Login / Signup

Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis.

Dereck R TaitMark HatherillOlivier Van Der MeerenAnn M GinsbergElana Van BrakelBruno SalaunThomas J ScribaElaine J AkiteHelen M AylesAnne BollaertsMarie-Ange DemoitiéAndreas DiaconThomas G EvansPaul GillardElizabeth HellströmJames C InnesMaria LempickiMookho MalahlehaNeil MartinsonDoris Mesia VelaMonde MuyoyetaVidelis NdubaThierry G PascalMichele TamerisFriedrich ThienemannRobert J WilkinsonFrançois Roman
Published in: The New England journal of medicine (2019)
Among adults infected with M. tuberculosis, vaccination with M72/AS01E elicited an immune response and provided protection against progression to pulmonary tuberculosis disease for at least 3 years. (Funded by GlaxoSmithKline Biologicals and Aeras; ClinicalTrials.gov number, NCT01755598.).
Keyphrases
  • pulmonary tuberculosis
  • mycobacterium tuberculosis
  • immune response
  • clinical trial
  • study protocol
  • phase iii
  • dendritic cells
  • emergency department